Drug Safety
Dr. John Cush RheumNow
3 years 11 months ago
Prolonging the Controversy of Hydroxychloroquine
Dr. Kathryn Dao (@KDAO2011 ) shares several abstracts from #ACR21 that addressed the topic of HCQ and cardiovascular safety.
https://t.co/J6sVzYJkUZ https://t.co/dBZmtwQ927
Robert B Chao, MD doctorRBC
3 years 11 months ago
Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment
⬆️ACR20 response compared to pbo
⬆️secondary endpoints
⭐️no new safety signals
Abs#453
#ACR21 #ACRBest @RheumNow
https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5
Olga Petryna DrPetryna
3 years 11 months ago
@RheumNow #acr21 abst 195 prospective study of JAKi for refractory Still’s in 7 pts suggests JAKs can be useful as an add on but not in monotherapy : partial response 57%& failure in43%. No patient achieved complete remission. steroids could be decreased by63%~ https://t.co/rYHVReRHvL
Tanmayee Bichile, MD BichileT
3 years 11 months ago
The evolving JAK inhibitor story
Black box Warnings regarding JAK inhibitor use and MACE, malignancy, thrombosis and mortality - full safety data remains to be examined.
@ACRheum #ACRambassador #ACR21 https://t.co/imQ1LSxeXM
EnvisionRheumat ERheumat
3 years 11 months ago
#ACR21 #ACR2021
Rheumatology Reproductive Health
👉🏻 Biologics and breast milk
👉🏻 Good vaccine response with TNFi (like with covid vaccines )
👉🏻 ustekimumab seems safe in pregnancy
👉🏻 Tofacitinib/ small molecules may cross placenta/ be in breast milk ➡️ contraindicated in preg/BF https://t.co/qk3sLR4QHz
Dr. John Cush RheumNow
3 years 11 months ago
COVaRiPad study - Immunosuppression affects COVID-19 vax Ab levels. 247 pts, 90% seroconverted but @ reduced (3.4 fold) titers. Lowest w/ MMF (21x) and B cell Rx vs MTX/AZA (3-4x). Pts on B cell therapy should wait 6 mos to recv vax #ACR21 Abstr# 0457 https://t.co/1gkCsJSDBk
Dr. Rachel Tate uptoTate
3 years 11 months ago
RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy
TheDaoIndex KDAO2011
3 years 11 months ago
Retrospective study of FAERS database: 186 irAE w/rheum manifestation
👉4.7% of all AEs
👉Arthritis, myositis, Sjogren, sarcoidosis were frequent
👉myositis assc w/ durvalumab, avelumab, atezolimumab and cemiplimab
#ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/t8UQWQicFc https://t.co/FGo6WCDQTp
TheDaoIndex KDAO2011
3 years 11 months ago
Retrospective study of cancer pts Rx w/ ICI and autoimmune Ab (ANA, RF, CCP, SSA/SSB, ANCA)
👉152 pts
👉59% had irAE
👉preICI Ab+⬆️odds of irAE (OR 17.5 95% CI 1.76-174, p=0.015)
👉strong assc b/t +RF and +CCP for ICD-arthritis
#ACR21 Abst#0440 @Rheumnow https://t.co/kUv5ddSAnY
Jeffrey Sparks MD MMSc jeffsparks
3 years 11 months ago
Large case-control study (n=8028) to identify baseline predictors of rheum irAEs after immune checkpoint inhibitor initiation for cancer.
Type of cancer (melanoma, GU), combination ICI, pre-existing autoimmune disease, and recent GC use each had higher odds of rheum irAE #ACR21 https://t.co/rHI6VQ37QB
Eric Dein ericdeinmd
3 years 11 months ago
@jhrheumatology Dr. Petri at #ACR21 Great Debate.
Safety issues with Voclosporin:
1) Nephrotoxicity
2) Infection
3) CV Risk Factors
4) Malignancy
5) Neurologic toxicity
6) Osteoporosis
7) Drug interactions
8) Deaths
9) Pregnancy contraindication
@RheumNow https://t.co/wjluivmKNt
TheDaoIndex KDAO2011
3 years 11 months ago
Experts (Drs. M Clowse, Sammaratino) limit mAb TNFi 1 month b/f delivery or extend dosing. But, they do dose again for flares. Risk for infection is low based on the PIANO registry. Postpartum, they restart the meds w/in 1 week (vag delivery), 2 weeks C/S @rheumnow #pregnancy
Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past decade, an armamentarium of biologic and targeted therapies has led to better control of disease activity in patients with rheumatoid arthritis. Whether these patients, especially those receiving newer biological and targeted therapies such as JAK inhibitors, are at an increased risk of severe COVID-19
Poster Hall